Twist Bioscience CORP Form 4 insider transactions

Twist Bioscience Corp. reports that Senior Vice President Dennis Cho sold shares to cover tax obligations related to vested Restricted Stock Units.

Emily M. Leproust, CEO and Director of Twist Bioscience Corp, reported transactions involving common stock and stock options.

Twist Bioscience Corp. reports that President and COO Patrick John Finn sold shares to cover tax withholding obligations upon the vesting of Restricted Stock Units.

Emily M. Leproust, CEO of Twist Bioscience Corp, reported transactions involving the sale of common stock and the acquisition of shares under a Rule 10b5-1 trading plan.

Twist Bioscience Corporation's Chief Financial Officer, Adam Laponis, has sold 4,000 shares of common stock as part of a pre-established Rule 10b5-1 trading plan.

Twist Bioscience Corporation CFO Adam Laponis sold 3,000 shares of common stock on April 14, 2026, pursuant to a pre-existing Rule 10b5-1 trading plan.

Twist Bioscience Corporation's Chief Financial Officer, Adam Laponis, reported a sale of 2,597 shares of common stock on April 9, 2026, to cover tax withholding obligations.

Melissa A. Starovasnik, a Director at Twist Bioscience Corp, reported a transaction involving the sale of 1,000 shares of common stock on April 1, 2026, executed under a pre-established Rule 10b5-1 trading plan.

Twist Bioscience Corp. director Robert Chess exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 trading plan.

Twist Bioscience's President and COO, Patrick John Finn, sold 4,294 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, sold 1,693 shares of common stock to cover tax withholding obligations related to RSU vesting.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 2,085 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience CEO Emily M. Leproust reported a non-discretionary sale of 7,205 common shares to cover tax withholding obligations related to vested restricted stock units.

Twist Bioscience SVP of Human Resources, Paula Green, sold 1,465 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience Senior VP Dennis Cho sold 844 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Twist Bioscience's SVP of Human Resources, Paula Green, reported the sale of 39,404 shares of common stock under a Rule 10b5-1 plan.

Twist Bioscience CFO Adam Laponis executed a planned sale of 7,000 common shares at $50 each, reducing his direct holdings.

Twist Bioscience's SVP, Chief Legal Officer, Dennis Cho, sold 5,000 shares of common stock for $49.93 per share under a pre-arranged 10b5-1 trading plan.

Twist Bioscience Chief Accounting Officer Robert F. Werner gifted 2,000 shares of common stock to a charitable organization.

Twist Bioscience Corp Director Keith Crandell was granted 5,095 shares of common stock as an annual equity award, vesting in 2026.

Twist Bioscience Director Katryn Blake acquired 5,095 shares of common stock through an annual equity award, bringing her total beneficial ownership to 19,448 shares.

A Twist Bioscience director reported the acquisition of shares from an equity award and a subsequent 'sell to cover' transaction for tax liabilities.

Twist Bioscience's President and COO, Patrick John Finn, sold 2,705 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Dennis Cho, SVP and Chief Legal Officer of Twist Bioscience, sold 1,099 shares to cover tax withholding obligations related to RSU vesting.

Twist Bioscience's Chief Accounting Officer, Robert F. Werner, reported sales of company common stock totaling 7,175 shares in early February 2026.

Twist Bioscience SVP of Human Resources, Paula Green, sold 1,194 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Twist Bioscience's President and COO, Patrick John Finn, sold 2,390 shares of common stock at $44.908 per share to cover tax withholding obligations related to restricted stock unit vesting.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 3,000 shares of common stock for $40 per share under a pre-arranged 10b5-1 trading plan.

Patrick John Finn, President and COO of Twist Bioscience Corp., executed a pre-arranged plan to exercise stock options and sell 23,279 shares of common stock.

Twist Bioscience's Chief Financial Officer, Adam Laponis, sold 2,738 shares of common stock at $35.261 per share to cover tax withholding obligations related to restricted stock unit vesting.